Therapeutics
|
OPPORTUNITY NUMBER |
OPPORTUNITY TITLE |
AGENCY NAME |
POSTED DATE |
CLOSE DATE |
|---|---|---|---|---|
| RFA-NS-22-016 | HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional) | HHS-NIH11 | 08/31/2021 | 11/03/2021 |
| RFA-AG-22-021 | Elucidating the Roles of Transposable Elements in AD/ADRD and Aging (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 07/14/2021 | 11/02/2021 |
| PAR-21-264 | Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) | HHS-NIH11 | 07/07/2021 | 11/01/2023 |
| PAR-21-246 | HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) | HHS-NIH11 | 07/06/2021 | 12/08/2022 |
| RFA-DA-22-029 | Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans Required) | HHS-NIH11 | 06/28/2021 | 10/14/2021 |
| RFA-ES-21-006 | CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 06/25/2021 | 09/20/2023 |
| PAR-21-240 | Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required) | HHS-NIH11 | 06/14/2021 | 03/11/2024 |
| PAR-21-241 | NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) | HHS-NIH11 | 06/14/2021 | 03/11/2024 |
| RFA-NS-21-029 | HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed) | HHS-NIH11 | 06/08/2021 | 10/10/2023 |
| RFA-DA-22-016 | Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33 Clinical Trials Not Allowed) | HHS-NIH11 | 06/04/2021 | 10/14/2021 |
| RFA-DK-21-016 | Characterization of Islet-derived Extracellular Vesicles for Improved Detection, Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 06/03/2021 | 11/03/2021 |
| PAS-21-216 | Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R01 - Clinical Trial Optional) | HHS-NIH11 | 04/16/2021 | 10/05/2021 |
| PAS-21-215 | Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R21 Clinical Trial Optional) | HHS-NIH11 | 04/16/2021 | 10/16/2021 |
| PAR-21-211 | Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required) | HHS-NIH11 | 04/01/2021 | 03/16/2024 |
| PAR-21-210 | Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required) | HHS-NIH11 | 04/01/2021 | 03/05/2024 |
| RFA-DK-21-004 | The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional) | HHS-NIH11 | 03/17/2021 | 03/09/2022 |
| RFA-NS-21-016 | HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed) | HHS-NIH11 | 03/11/2021 | 10/10/2023 |
| PAR-21-123 | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) | HHS-NIH11 | 03/11/2021 | 02/20/2024 |
| PAR-21-124 | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) | HHS-NIH11 | 03/11/2021 | 02/20/2024 |
| PAR-21-122 | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) | HHS-NIH11 | 03/11/2021 | 02/20/2024 |
| PAR-21-131 | Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-135 | Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-129 | Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-130 | Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-137 | Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-136 | Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-134 | Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| PAR-21-132 | Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) | HHS-NIH11 | 03/02/2021 | 02/15/2024 |
| RFA-DA-22-010 | Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional) | HHS-NIH11 | 02/26/2021 | 10/25/2022 |
| RFA-DA-22-008 | NIH Blueprint for Neuroscience Research: Tools and Technologies to Explore Nervous System Biomolecular Condensates (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 01/25/2021 | 09/15/2021 |
| PAR-21-100 | Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional) | HHS-NIH11 | 12/23/2020 | 02/05/2023 |
| PAR-21-073 | NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional) | HHS-NIH11 | 12/01/2020 | 06/09/2023 |
| PAR-21-033 | National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | HHS-NIH11 | 11/12/2020 | 01/07/2024 |
| RFA-AI-20-076 | New Technologies for the In vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 10/20/2020 | 03/17/2023 |
| PAR-20-300 | Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional) | HHS-NIH11 | 09/11/2020 | 12/09/2022 |
| PAR-20-299 | Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) | HHS-NIH11 | 09/11/2020 | 12/09/2022 |
| PAR-20-293 | Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional) | HHS-NIH11 | 09/10/2020 | 05/17/2023 |
| PAR-20-292 | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | HHS-NIH11 | 08/24/2020 | 07/20/2022 |
| PAR-20-264 | Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 08/10/2020 | 09/07/2023 |
| PAR-20-263 | Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 08/10/2020 | 09/07/2023 |
| PAR-20-253 | Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 07/07/2020 | 05/30/2023 |
| PAR-20-180 | Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional) | NIH | 04/30/2020 | 09/07/2023 |
| PAR-20-161 | Catalyzing Innovation in Pediatric Pharmacology Clinical Trial Design and Resource Access (X01 Clinical Trial Not Allowed) | NIH | 04/02/2020 | 03/17/2023 |
| PAR-20-157 | Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) | NIH | 03/31/2020 | 05/07/2023 |
| PAR-20-159 | Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) | NIH | 03/31/2020 | 05/07/2023 |
| PA-20-146 | NIDA Small Research Grant Program (R03 Clinical Trial Required) | NIH | 03/24/2020 | 05/07/2023 |
| PAR-20-116 | Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) | NIH | 02/24/2020 | 11/18/2021 |
| RFA-OD-20-004 | INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed) | NIH | 12/13/2019 | 11/03/2021 |
| PAR-20-072 | NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) | NIH | 12/09/2019 | 09/07/2022 |
| PAR-20-063 | NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed) | NIH | 11/22/2019 | 01/07/2023 |
| PAR-19-385 | Environmental Risks for Psychiatric Disorders: Biological Basis of Pathophysiology (R21 Clinical Trial Not Allowed) | NIH | 09/30/2019 | 11/16/2021 |
| PAR-19-386 | Environmental Risks for Psychiatric Disorders: Biological Basis of Pathophysiology (R01 Clinical Trial Not Allowed) | NIH | 09/30/2019 | 11/16/2021 |
| PAR-19-357 | Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed) | HHS | 09/03/2019 | 01/10/2022 |
| PAR-19-364 | Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed) | HHS | 09/03/2019 | 01/10/2022 |
| PAR-19-356 | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | HHS | 08/28/2019 | 07/20/2022 |
| PAR-19-328 | Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | HHS | 08/05/2019 | 09/08/2022 |
| PAR-19-325 | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | NIH | 07/30/2019 | 02/11/2022 |
| PAR-19-305 | Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional) | NIH | 06/25/2019 | 07/16/2022 |
| PAR-19-304 | Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional) | NIH | 06/25/2019 | 07/16/2022 |
| PAR-19-294 | Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) | NIH | 06/06/2019 | 11/12/2021 |
| PAR-19-289 | Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) | NIH | 05/29/2019 | 09/07/2022 |
| PAR-19-278 | Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) | NIH | 05/08/2019 | 12/17/2021 |
| PA-19-237 | Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed) | NIH | 04/03/2019 | 05/07/2022 |
| PAR-19-194 | Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed) | NIH | 02/22/2019 | 05/07/2022 |
| PAR-19-193 | Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed) | NIH | 02/22/2019 | 05/07/2022 |
| PAR-19-189 | Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) | NIH | 02/21/2019 | 01/07/2022 |
| PAR-19-078 | Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed) | NIH | 11/26/2018 | 01/07/2022 |
| PA-19-082 | Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R01 Clinical Trial Not Allowed) | NIH | 11/26/2018 | 01/07/2022 |
| PA-19-083 | Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R21 Clinical Trial Not Allowed) | NIH | 11/26/2018 | 01/07/2022 |
| PA-19-067 | Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed) | NIH | 11/13/2018 | 01/07/2022 |
| PA-19-066 | Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed) | NIH | 11/13/2018 | 01/07/2022 |
| PA-19-020 |
Fc-Dependent Mechanisms of Antibody-Mediated Killing (R21 Clinical Trial Not Allowed) | NIH | 10/5/2018 | 1/7/2022 |
| PAR-18-952 |
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed) | NIH | 10/4/2018 | 10/25/2021 |
| PAR-18-953 |
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) | NIH | 10/4/2018 | 10/25/2021 |
| PA-18-937 | Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional) | NIH | 9/26/2018 | 1/7/2022 |
|
Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed) |
NIH |
9/26/2018 |
1/7/2022 |
|
|
Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional) |
NIH |
9/10/2018 |
9/7/2021 |